These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33430681)

  • 1. Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
    Kouamou V; Mavetera J; Manasa J; Ndhlovu CE; Katzenstein D; McGregor AM
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):776-783. PubMed ID: 33430681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
    Elwitigala J; Rajapaksa L; Inzaule SC; Ariyaratne KAM; Jayasena S; Kurle S; Patil A; Kale D; Siriwardna L; Samaraweera G; Perera H; Jayakody C
    J Antimicrob Chemother; 2023 Jun; 78(6):1476-1479. PubMed ID: 37071590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
    Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
    J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis.
    Bertagnolio S; Hermans L; Jordan MR; Avila-Rios S; Iwuji C; Derache A; Delaporte E; Wensing A; Aves T; Borhan ASM; Leenus A; Parkin N; Doherty M; Inzaule S; Mbuagbaw L
    J Infect Dis; 2021 Aug; 224(3):377-388. PubMed ID: 33202025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
    AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey.
    Ávila-Ríos S; García-Morales C; Valenzuela-Lara M; Chaillon A; Tapia-Trejo D; Pérez-García M; López-Sánchez DM; Maza-Sánchez L; Del Arenal-Sánchez SJ; Paz-Juárez HE; Quiroz-Morales VS; Mehta SR; Smith DM; León-Juárez EA; Magis-Rodríguez C; Reyes-Terán G;
    J Antimicrob Chemother; 2019 Apr; 74(4):1044-1055. PubMed ID: 30597094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV drug resistance in persons initiating or reinitiating first-line antiretroviral therapy in Paraguay: Results of a National Patient Survey.
    Aguilar G; Truong HM; Ovelar P; Samudio T; Lopez G; García-Morales C; Tapia-Trejo D; López-Sánchez DM; Ávila-Ríos S; Giron A; De Arias AR; Rios-Gonzalez C; McFarland W
    J Med Virol; 2022 Oct; 94(10):5061-5065. PubMed ID: 35701340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment.
    Hermans LE; Hofstra LM; Schuurman R; Ter Heine R; Burger DM; Talboom SAJ; De Jong D; Tempelman HA; Venter WDF; Nijhuis M; Wensing AMJ
    AIDS; 2022 Jun; 36(7):923-931. PubMed ID: 35113046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
    Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK
    J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment HIV drug resistance among adults initiating ART in Namibia.
    Taffa N; Roscoe C; Sawadogo S; De Klerk M; Baughman AL; Wolkon A; Mutenda N; DeVos J; Zheng DP; Wagar N; Prybylski D; Yang C; Hamunime N; Agolory S; Raizes E
    J Antimicrob Chemother; 2018 Nov; 73(11):3137-3142. PubMed ID: 30137412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.
    Kiros M; Biset S; Gebremariam B; Yalew GT; Abegaz WE; Geteneh A
    Virol J; 2023 Oct; 20(1):243. PubMed ID: 37880705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.